應用分類
NGS Instrument
Benchtop sequencing systems
Key specifications | iSeq 100 System | MiniSeq System | MiSeq System | MiSeq i100 Series | NextSeq 1000 and 2000 Systems |
|---|---|---|---|---|---|
Number of kit configurations | 5 | 5 | 9 | 10 | 14 |
Output range | 144 Mb–1.2 Gb | 1.65–7.5 Gb | 300 Mb–15 Gb | 1.5–30 Gb | 10–540 Gb |
Run time (range) | 9.5–19 hr | 5–24 hr | 5.5–56 hr | ~4–15.5 hr | 8–44 hr |
Max reads per run (single reads) | 4M | 25M | 25M | 100M | 1.8B |
Max read length | 2 × 150 bp | 2 × 150 bp | 2 × 300 bp | 2 × 300 bp | 2 × 300 bp |
Production-scale sequencers
Key specifications | NextSeq 1000 and 2000 Systems | NovaSeq 6000 System | NovaSeq X Series |
|---|---|---|---|
Max read length | 2 × 300 bp | 2 × 250 bp | 2 × 150 bp |
Max reads per run (single reads) | 1.8Ba | 10B (single flow cell)b
20B (dual flow cells)b | 26B (single flow cell)c
52B (dual flow cells)c,f |
Run time (range)d | ~8–44 hr | ~13–44 hr | ~17–48 hr |
Max output per flow cell | 540 Gba | 3 Tbb | 8 Tbc |
Sequencing platforms
Trusted technology and proven performance empower scientists to explore further, with confidence. View benchtop and production-scale sequencers, compare features, and learn how to choose the right next-generation sequencing (NGS) platform for your needs.
illumina Panel
TruSight Oncology 500 | TruSight Oncology 500 High-Throughput | TruSight Oncology 500 ctDNA v2 | |
|---|---|---|---|
TSO 500 HRD -- NextSeq 550, NextSeq 550Dx in Research Mode, NovaSeq 6000 SP Flow Cell | NovaSeq 6000Dx in RUO Mode a
NovaSeq X Seriesa | ||
FFPE (DNA and RNA) | FFPE (DNA and RNA) | Blood (cfDNA) | |
DNA variants | 523 genes for DNA variants | 523 genes for DNA variants | 523 genes for DNA variants |
55 genes for RNA fusions and splice variants | 55 genes for RNA fusions and splice variants | 23 genes for DNA fusions | |
Variants called | SNVs
InDels
CNVs
Fusions
Splice variants
Genomic signatures
| SNVs
InDels
CNVs
Fusions
Splice variants
| SNVs
InDels
CNVs
Fusions (from DNA)
|
Genomic signatures | TMB (Immuno-Oncology)
MSI (Immuno-Oncology)
HRD - Through addition of TSO 500
HRD kit | TMB (Immuno-Oncology)
MSI (Immuno-Oncology) |
TMB (Immuno-Oncology)
MSI (Immuno-Oncology) |
Panel size | 1.94 Mb DNA; 358 kb RNA | 1.94 Mb DNA; 358 kb RNA | 1.94 Mb DNA |
Approximate Turnaround Time | 4–5 days | 4–5 days | 3-4 days |
Sequencing Platforms | TSO 500 -- NextSeq 500, NextSeq 550, NextSeq550Dx in Research Mode
TSO 500 HRD -- NextSeq 550, NextSeq 550Dx in Research Mode, NovaSeq 6000 SP Flow Cell | NextSeq 1000 & 2000a
NovaSeq 6000
NovaSeq 6000Dx in RUO Mode a
NovaSeq X Seriesa | NovaSeq 6000
NovaSeq 6000Dx in RUO Mode a
NovaSeq X |
Sample Batching | TSO 500 -- 8 samples/run
TSO 500 HRD -- 8-16 samples/run | 8-36 samples/run (NextSeq 1000 & 2000)
16–192 samples/run (NovaSeq 6000)
32-480 samples/run (NovaSeq X)
32-960 samples/run (NovaSeq X Plus) | 8–48 samples/run |
Sample input | 40 ng DNA
40 ng RNA | 40 ng DNA
40–80 ng RNA | 20 ng cfDNA (10–30 ng possible) |
Analytical Specificity | 99.9998% | 99.9998% | 99.9994% (SNVs) |
Analytical Sensitivity | >96% | >96% | >95% |
Portfolio offers flexibility based on available sample type:
-
Separate pan-cancer assays to support tissue (FFPE) or liquid (blood) biopsies
-
Opportunity for unique tumor insights, leveraging similar DNA panel design
-
Similar workflow design to standardize sequencing and bioinformatics platforms
-
Liquid biopsy option when tissue samples may not be accessible (e.g. tumor location or size, patient health), quantity insufficient or delayed
-
Content specifications：Probes enrich for full coding sequences of 170 genes. Calls single nucleotide variants, small insertions, and deletions in 151 genes, amplifications in 59 genes, and fusions plus splice variants in 55 genes.
-
Description：Perform comprehensive somatic variant detection research in solid tumors using variant calling information from both DNA and RNA.
-
Hands-on time：~10.5 hr
-
Input quantity：40 ng DNA and/or RNA
-
Instruments：NextSeq 550 System, NextSeq 500 System
-
Content specifications：DNA and RNA targets for 52 oncogenes
-
Description：Somatic analysis research on 52 genes associated with solid tumor cancers.
-
Hands-on time：< 1.5 hr
-
Input quantity：1–100 ng (10 ng recommended per pool)
-
Instruments：MiSeq System, iSeq 100 System, MiSeqDx in Research Mode, MiniSeq System
-
Content specifications：DNA and RNA targets for 161 oncogenes
-
Description：Somatic analysis research on hotspot and full-length targets of genes* associated with solid tumor cancers.
-
Hands-on time：< 1.5 hr
-
Input quantity：1–100 ng (10 ng recommended per pool)
-
Instruments：NextSeq 550 System, NextSeq 2000 System, NextSeq 1000 System, NextSeq 550Dx in Research Mode
-
Hands-on time：< 1.5 hr
-
Input quantity：10 ng high-quality DNA or RNA
-
Instruments：MiSeq System, NextSeq 550 System, NextSeq 2000 System, NextSeq 1000 System, MiSeqDx in Research Mode, MiniSeq System
-
Content specifications：DTargets biomarkers across 69 genes (40 key DNA target genes, 29 RNA fusion driver genes, and 5 gene expression levels)
-
Description：Targeted panel to study 40 DNA genes, 29 RNA fusion driver genes, and 5 gene expression levels associated with myeloid cancers.
-
Hands-on time：< 1.5 hr
-
Input quantity：20 ng high-quality DNA; 10 ng high-quality RNA
(10 ng recommended per pool) -
Instruments：MiSeq System, MiniSeq System
-
Content specifications：Exonic regions and the flanking intronic sequences of the BRCA1 and BRCA2
-
Description：Germline and somatic analysis studies of BRCA1 and BRCA2.
-
Hands-on time：< 1.5 hr
-
Input quantity：1–100 ng (10 ng recommended per pool)
-
Instruments：MiSeq System, iSeq 100 System, MiSeqDx in Research Mode, MiniSeq System
-
Content specifications：Hotspot regions of 50 genes with known associations to cancer
-
Description：Somatic analysis research into hotspot regions of 50 cancer-related genes.
-
Hands-on time：< 1.5 hr
-
Input quantity：1–100 ng (10 ng recommended per pool)
-
Instruments：MiSeq System, iSeq 100 System, MiSeqDx in Research Mode, MiniSeq System
-
Content specifications：Custom content of interest - up to 5 Mb
-
Description：A custom research assay that can be used to focus studies on specific genes, regions, or variants of interest with high accuracy.
-
Hands-on time：1.5 hr
-
Input quantity：1–100 ng (10 ng recommended per pool)
-
Instruments：MiSeq System, iSeq 100 System, NextSeq 550 System, NextSeq 2000 System, NextSeq 1000 System, MiSeqDx in Research Mode, MiniSeq System, NextSeq 550Dx in Research Mode
Pan-cancer Panel
CGP
CGP allows for a better definition of the key gene alterations in different moments of the life of patients with cancer
Obtain an expanded report of biomarkers and genomic signatures that can reveal treatment possibilities for your patients without sacrificing valuable time.
CGP reveals key actionable biomarkers across multiple solid tumor types.
Comprehensive genomic coverage
Small targeted panels provide results on a limited subset of biomarkers. CGP tests more broadly to obtain a more complete set of biomarkers and genomic signatures for each patient tested.
“[CGP] is something that we are doing regularly withour patients and that we know is really crucial fordefining the best treatment strategy.”
AML MRD
Oncology Research
The heterogeneity and dynamism of cancer present formidable challenges to treating the disease. Through an iterative process of mutation and cell expansion, tumors generate genetic and phenotypic heterogeneity, contributing to the complexity of the disease.
scDNA AML MRD panel
The complexity of leukemia clonal architecture and the genotypic and phenotypic drifts during treatment explain why more than half of patients in remission could relapse. Addressing these with single-cell multiomics enables you to go beyond a binary MRD readout to gain crucial biomarker insights.
Precision Medicine
Resolving complex biology at the single cell level is crucial to the understanding of disease and ultimately unlocking novel therapies. While advances have been made in precision medicine, challenges in fully understanding disease profiles at the clonal level and comprehensive characterization of ex vivo cell therapeutics remain.
Genome Editing
Genome engineering techniques, like CRISPR, result in heterogeneous editing outcomes that include variations in zygosity, off-target effects, co-occurring multiplex edits, chromosomal translocations, and changes to genome stability. Measuring these outcomes accurately cannot be done by traditional sequencing without lengthy clonal outgrowth steps and hours of computational work.
Genome integrity
Genome integrity is essential for predicting therapeutic safety and patient outcomes, whether dealing with cell-based therapies or analyzing heterogeneous tumors. Traditional methods for assessing genome stability are often limited by low throughput or time-consuming clonal outgrowth processes.
Targeted Panel
ACCU1N Next Generation BRCAl/2 Gene Analysis
The ACCUiN Next Generation BRCAl/2 Gene Analysis testing is designed for detecting genetic mutations in the testing specimens. It assesses the mutation status in human BRCAl and BRCA2 genes. The testing encompasses single nucleotide variants (SNVs), insertions, deletions, and insertion-deletions (INDELs) mutations
APPLICABLE POPULATIONS
Diagnosed by clinical physicians as:
• Breast cancer patients
• Ovarian cancer patients
• Prostate cancer patients
• Pancreatic cancer patients
• Cancer patients/individuals with a family history of cancer
ACCUiN Next Generation Cancer Gene Analysis
The ACCUiN Next Generation Cancer Gene Analysis testing is designed for detecting genetic mutations in malignant solid tumor tissues. It assesses the mutation status in human oncogenes, including ALK 、 BRAF 、 EGFR 、 ERBB2 、 ESRl 、 GNAS 、 KIT 、 KRAS 、 MET 、 NRAS 、 PDGFRA 、 PIK3CA and ROSl The testing encompasses single nucleotide variants (SNVs), insertions, deletions, and insertion-deletions (INDELs) mutations.
APPLICABLE POPULATIONS
Diagnosed by clinical physicians as:
• Lung cancer patients
• Breast cancer patients
• Colorectal (colon, rectum, cecum) cancer patients
• Gastrointestinal stromal tumor (GIST) patients
• Melanoma patients
• Other solid tumor patients